共 50 条
- [25] Comment on: ‘Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition’ Applied Health Economics and Health Policy, 2020, 18 : 453 - 454
- [28] VALUE-BASED PRICING IN COLOMBIA: THE DEVIL IS IN THE DETAILS VALUE IN HEALTH, 2021, 24 : S152 - S152